Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 386

2.

Pharmacokinetic assessment of alprazolam-induced neonatal abstinence syndrome using physiologically based pharmacokinetic model.

Yamamoto K, Fukushima S, Mishima Y, Hashimoto M, Yamakawa K, Fujioka K, Iijima K, Yano I.

Drug Metab Pharmacokinet. 2019 Sep 19. pii: S1347-4367(19)30121-1. doi: 10.1016/j.dmpk.2019.09.002. [Epub ahead of print]

PMID:
31699653
3.

Antibiotic de-escalation therapy in patients with community-acquired nonbacteremic pneumococcal pneumonia.

Uda A, Tokimatsu I, Koike C, Osawa K, Shigemura K, Kimura T, Miyara T, Yano I.

Int J Clin Pharm. 2019 Oct 25. doi: 10.1007/s11096-019-00926-z. [Epub ahead of print]

PMID:
31654366
4.

Efficacy of educational intervention on reducing the inappropriate use of oral third-generation cephalosporins.

Uda A, Kimura T, Nishimura S, Ebisawa K, Ohji G, Kusuki M, Yahata M, Izuta R, Sakaue T, Nakamura T, Koike C, Tokimatsu I, Yano I, Iwata K, Miyara T.

Infection. 2019 Oct 11. doi: 10.1007/s15010-019-01362-x. [Epub ahead of print]

PMID:
31605309
5.

[Clinical Pharmacometrics for Rational Drug Treatment].

Yano I.

Yakugaku Zasshi. 2019;139(10):1227-1234. doi: 10.1248/yakushi.19-00124. Japanese.

7.

A Minimal Physiologically-Based Pharmacokinetic Model for Tacrolimus in Living-Donor Liver Transplantation: Perspectives Related to Liver Regeneration and the cytochrome P450 3A5 (CYP3A5) Genotype.

Itohara K, Yano I, Tsuzuki T, Uesugi M, Nakagawa S, Yonezawa A, Okajima H, Kaido T, Uemoto S, Matsubara K.

CPT Pharmacometrics Syst Pharmacol. 2019 Aug;8(8):587-595. doi: 10.1002/psp4.12420. Epub 2019 Jun 9.

8.

Bitterness-Masking Effects of Different Beverages on Zopiclone and Eszopiclone Tablets.

Yoshida M, Kojima H, Uda A, Haraguchi T, Ozeki M, Kawasaki I, Yamamoto K, Yano I, Hirai M, Uchida T.

Chem Pharm Bull (Tokyo). 2019;67(5):404-409. doi: 10.1248/cpb.c18-00502.

9.

Concentration and Glycoform of Rituximab in Plasma of Patients with B Cell Non-Hodgkin's Lymphoma.

Yonezawa A, Otani Y, Kitano T, Mori M, Masui S, Isomoto Y, Tsuda M, Imai S, Ikemi Y, Denda M, Sato Y, Nakagawa S, Omura T, Nakagawa T, Yano I, Hayakari M, Takaori-Kondo A, Matsubara K.

Pharm Res. 2019 Apr 15;36(6):82. doi: 10.1007/s11095-019-2624-5.

PMID:
30989405
10.

Cationized liposomal keto-mycolic acids isolated from Mycobacterium bovis bacillus Calmette-Guérin induce antitumor immunity in a syngeneic murine bladder cancer model.

Yoshino T, Miyazaki J, Kojima T, Kandori S, Shiga M, Kawahara T, Kimura T, Naka T, Kiyohara H, Watanabe M, Yamasaki S, Akaza H, Yano I, Nishiyama H.

PLoS One. 2019 Jan 4;14(1):e0209196. doi: 10.1371/journal.pone.0209196. eCollection 2019.

11.

Association of CYP2D6 polymorphisms and extrapyramidal symptoms in schizophrenia patients receiving risperidone: a retrospective study.

Ito T, Yamamoto K, Ohsawa F, Otsuka I, Hishimoto A, Sora I, Hirai M, Yano I.

J Pharm Health Care Sci. 2018 Nov 19;4:28. doi: 10.1186/s40780-018-0126-y. eCollection 2018.

12.

Effects of fasting on warfarin sensitivity index in patients undergoing cardiovascular surgery.

Katada Y, Nakagawa S, Nishimura A, Sato YK, Taue H, Matsumura K, Yamazaki K, Minakata K, Yano I, Omura T, Imai S, Yonezawa A, Sato Y, Nakagawa T, Minatoya K, Matsubara K.

Eur J Clin Pharmacol. 2019 Apr;75(4):561-568. doi: 10.1007/s00228-018-2592-4. Epub 2018 Nov 21.

PMID:
30460405
13.

Ubiquitin ligase HMG-CoA reductase degradation 1 (HRD1) prevents cell death in a cellular model of Parkinson's disease.

Omura T, Matsuda H, Nomura L, Imai S, Denda M, Nakagawa S, Yonezawa A, Nakagawa T, Yano I, Matsubara K.

Biochem Biophys Res Commun. 2018 Nov 30;506(3):516-521. doi: 10.1016/j.bbrc.2018.10.094. Epub 2018 Oct 22.

PMID:
30361093
14.

Oxicam-derived non-steroidal anti-inflammatory drugs suppress 1-methyl-4-phenyl pyridinium-induced cell death via repression of endoplasmic reticulum stress response and mitochondrial dysfunction in SH-SY5Y cells.

Omura T, Sasaoka M, Hashimoto G, Imai S, Yamamoto J, Sato Y, Nakagawa S, Yonezawa A, Nakagawa T, Yano I, Tasaki Y, Matsubara K.

Biochem Biophys Res Commun. 2018 Sep 18;503(4):2963-2969. doi: 10.1016/j.bbrc.2018.08.078. Epub 2018 Aug 11.

PMID:
30107908
15.

Efficacy and Safety of the Traditional Japanese Medicine Keigairengyoto in the Treatment of Acne Vulgaris.

Ito K, Masaki S, Hamada M, Tokunaga T, Kokuba H, Tashiro K, Yano I, Yasumoto S, Imafuku S.

Dermatol Res Pract. 2018 Jul 2;2018:4127303. doi: 10.1155/2018/4127303. eCollection 2018.

16.

Study of specific nanoenvironments containing α-helices in all-α and (α+β)+(α/β) proteins.

Mazoni I, Borro LC, Jardine JG, Yano IH, Salim JA, Neshich G.

PLoS One. 2018 Jul 10;13(7):e0200018. doi: 10.1371/journal.pone.0200018. eCollection 2018.

17.

Pharmacokinetics and Pharmacodynamics of Once-Daily Tacrolimus Compared With Twice-Daily Tacrolimus in the Early Stage After Living Donor Liver Transplantation.

Iwasaki M, Yano I, Fukatsu S, Hashi S, Yamamoto Y, Sugimoto M, Fukudo M, Masuda S, Nakagawa S, Yonezawa A, Kaido T, Uemoto S, Matsubara K.

Ther Drug Monit. 2018 Dec;40(6):675-681. doi: 10.1097/FTD.0000000000000551.

PMID:
29965882
18.

Effects of Cryotherapy on Objective and Subjective Symptoms of Paclitaxel-Induced Neuropathy: Prospective Self-Controlled Trial.

Hanai A, Ishiguro H, Sozu T, Tsuda M, Yano I, Nakagawa T, Imai S, Hamabe Y, Toi M, Arai H, Tsuboyama T.

J Natl Cancer Inst. 2018 Feb 1;110(2):141-148. doi: 10.1093/jnci/djx178.

19.

Association of Expression Levels or Activation Status of STAT3 with Treatment Outcomes of Sunitinib in Patients with Renal Cell Carcinoma.

Yamamoto K, Hara T, Nakagawa T, Hirai M, Miyake H, Fujisawa M, Yano I.

Target Oncol. 2018 Jun;13(3):371-378. doi: 10.1007/s11523-018-0563-4.

PMID:
29633072
20.

Bacillus Calmette-Guérin strain differences as the basis for immunotherapies against bladder cancer.

Miyazaki J, Onozawa M, Takaoka E, Yano I.

Int J Urol. 2018 May;25(5):405-413. doi: 10.1111/iju.13538. Epub 2018 Mar 5. Review.

21.

Compatibility and Stability of Nab-Paclitaxel in Combination with Other Drugs.

Mizuta N, Nakagawa T, Yamamoto K, Nishioka T, Kume M, Makimoto H, Yano I, Minami H, Hirai M.

Kobe J Med Sci. 2017 Jul 20;63(1):E9-E16.

22.

Pharmacokinetic and Pharmacodynamic Markers of Mycophenolic Acid Associated with Effective Prophylaxis for Acute Graft-Versus-Host Disease and Neutrophil Engraftment in Cord Blood Transplant Patients.

Yoshimura K, Yano I, Yamamoto T, Kondo T, Kawanishi M, Isomoto Y, Yonezawa A, Takaori-Kondo A, Matsubara K.

Biol Blood Marrow Transplant. 2018 Jul;24(7):1441-1448. doi: 10.1016/j.bbmt.2018.01.040. Epub 2018 Feb 7.

23.

Genetic polymorphisms associated with adverse reactions of molecular-targeted therapies in renal cell carcinoma.

Yamamoto K, Yano I.

Med Oncol. 2018 Jan 4;35(2):16. doi: 10.1007/s12032-017-1077-0. Review.

PMID:
29302760
24.

Long-term efficacy of comprehensive multidisciplinary antibiotic stewardship programs centered on weekly prospective audit and feedback.

Kimura T, Uda A, Sakaue T, Yamashita K, Nishioka T, Nishimura S, Ebisawa K, Nagata M, Ohji G, Nakamura T, Koike C, Kusuki M, Ioroi T, Mukai A, Abe Y, Yoshida H, Hirai M, Arakawa S, Yano I, Iwata K, Tokimatsu I.

Infection. 2018 Apr;46(2):215-224. doi: 10.1007/s15010-017-1099-8. Epub 2017 Nov 13.

PMID:
29134582
25.

Anti-tumor immunity via the superoxide-eosinophil axis induced by a lipophilic component of Mycobacterium lipomannan.

Ito T, Hirahara K, Onodera A, Koyama-Nasu R, Yano I, Nakayama T.

Int Immunol. 2017 Nov 1;29(9):411-421. doi: 10.1093/intimm/dxx051.

PMID:
29099969
26.

Population pharmacokinetics and pharmacodynamics of mycophenolic acid using the prospective data in patients undergoing hematopoietic stem cell transplantation.

Yoshimura K, Yano I, Yamamoto T, Kawanishi M, Isomoto Y, Yonezawa A, Kondo T, Takaori-Kondo A, Matsubara K.

Bone Marrow Transplant. 2018 Jan;53(1):44-51. doi: 10.1038/bmt.2017.213. Epub 2017 Oct 9.

PMID:
28991252
27.

Effects of Ascorbyl-2-phosphate Magnesium on Human Keratinocyte Toxicity and Pathological Changes by Sorafenib.

Yamamoto K, Shichiri H, Ishida T, Kaku K, Nishioka T, Kume M, Makimoto H, Nakagawa T, Hirano T, Bito T, Nishigori C, Yano I, Hirai M.

Biol Pharm Bull. 2017;40(9):1530-1536. doi: 10.1248/bpb.b17-00386.

28.

Efficacy of protocol-based pharmacotherapy management on anticoagulation with warfarin for patients with cardiovascular surgery.

Katada Y, Nakagawa S, Minakata K, Odaka M, Taue H, Sato Y, Yonezawa A, Kayano Y, Yano I, Nakatsu T, Sakamoto K, Uehara K, Sakaguchi H, Yamazaki K, Minatoya K, Sakata R, Matsubara K.

J Clin Pharm Ther. 2017 Oct;42(5):591-597. doi: 10.1111/jcpt.12560. Epub 2017 May 15.

PMID:
28503837
29.

Association of Single Nucleotide Polymorphisms in STAT3, ABCB1, and ABCG2 with Stomatitis in Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib: A Retrospective Analysis in Japanese Patients.

Watanabe A, Yamamoto K, Ioroi T, Hirata S, Harada K, Miyake H, Fujisawa M, Nakagawa T, Yano I, Hirai M.

Biol Pharm Bull. 2017;40(4):458-464. doi: 10.1248/bpb.b16-00875.

30.

Prostaglandin E1 reduces the keratinocyte toxicity of sorafenib by maintaining signal transducer and activator of transcription 3 (STAT3) activity and enhancing the cAMP response element binding protein (CREB) activity.

Shichiri H, Yamamoto K, Tokura M, Ishida T, Uda A, Bito T, Nishigori C, Nakagawa T, Hirano T, Yano I, Hirai M.

Biochem Biophys Res Commun. 2017 Apr 1;485(2):227-233. doi: 10.1016/j.bbrc.2017.02.107. Epub 2017 Feb 24.

PMID:
28237700
31.

Population Pharmacokinetics of Topiramate in Japanese Pediatric and Adult Patients With Epilepsy Using Routinely Monitored Data.

Takeuchi M, Yano I, Ito S, Sugimoto M, Yamamoto S, Yonezawa A, Ikeda A, Matsubara K.

Ther Drug Monit. 2017 Apr;39(2):124-131. doi: 10.1097/FTD.0000000000000383.

PMID:
28230619
32.

Time-Dependent Structural Alteration of Rituximab Analyzed by LC/TOF-MS after a Systemic Administration to Rats.

Otani Y, Yonezawa A, Tsuda M, Imai S, Ikemi Y, Nakagawa S, Omura T, Nakagawa T, Yano I, Matsubara K.

PLoS One. 2017 Jan 4;12(1):e0169588. doi: 10.1371/journal.pone.0169588. eCollection 2017.

33.

Potentially inappropriate medications in elderly Japanese patients: effects of pharmacists' assessment and intervention based on Screening Tool of Older Persons' Potentially Inappropriate Prescriptions criteria ver.2.

Kimura T, Ogura F, Yamamoto K, Uda A, Nishioka T, Kume M, Makimoto H, Yano I, Hirai M.

J Clin Pharm Ther. 2017 Apr;42(2):209-214. doi: 10.1111/jcpt.12496. Epub 2016 Dec 31.

PMID:
28039932
34.

C-Type Lectin Receptor DCAR Recognizes Mycobacterial Phosphatidyl-Inositol Mannosides to Promote a Th1 Response during Infection.

Toyonaga K, Torigoe S, Motomura Y, Kamichi T, Hayashi JM, Morita YS, Noguchi N, Chuma Y, Kiyohara H, Matsuo K, Tanaka H, Nakagawa Y, Sakuma T, Ohmuraya M, Yamamoto T, Umemura M, Matsuzaki G, Yoshikai Y, Yano I, Miyamoto T, Yamasaki S.

Immunity. 2016 Dec 20;45(6):1245-1257. doi: 10.1016/j.immuni.2016.10.012. Epub 2016 Nov 22.

35.

Population Pharmacokinetics of Everolimus in Relation to Clinical Outcomes in Patients With Advanced Renal Cell Carcinoma.

Tanaka A, Yano I, Shinsako K, Sato E, Fukudo M, Masuda S, Yamasaki T, Kamba T, Ogawa O, Matsubara K.

Ther Drug Monit. 2016 Dec;38(6):663-669.

PMID:
27661398
36.

Effect of vitamin K2 on the anticoagulant activity of warfarin during the perioperative period of catheter ablation: Population analysis of retrospective clinical data.

Zhou Z, Yano I, Odaka S, Morita Y, Shizuta S, Hayano M, Kimura T, Akaike A, Inui K, Matsubara K.

J Pharm Health Care Sci. 2016 Aug 4;2:17. doi: 10.1186/s40780-016-0053-8. eCollection 2016.

37.

Disruption of Slc52a3 gene causes neonatal lethality with riboflavin deficiency in mice.

Yoshimatsu H, Yonezawa A, Yamanishi K, Yao Y, Sugano K, Nakagawa S, Imai S, Omura T, Nakagawa T, Yano I, Masuda S, Inui K, Matsubara K.

Sci Rep. 2016 Jun 8;6:27557. doi: 10.1038/srep27557.

38.

Multiple structure single parameter: analysis of a single protein nano environment descriptor characterizing a shared loci on structurally aligned proteins.

Salim JA, Borro L, Mazoni I, Yano I, Jardine JG, Neshich G.

Bioinformatics. 2016 Jun 15;32(12):1885-7. doi: 10.1093/bioinformatics/btw082. Epub 2016 Feb 15.

PMID:
27153716
39.

Population Pharmacokinetic Modeling of Levetiracetam in Pediatric and Adult Patients With Epilepsy by Using Routinely Monitored Data.

Ito S, Yano I, Hashi S, Tsuda M, Sugimoto M, Yonezawa A, Ikeda A, Matsubara K.

Ther Drug Monit. 2016 Jun;38(3):371-8. doi: 10.1097/FTD.0000000000000291.

PMID:
26913593
40.

Significant effect of age on docetaxel pharmacokinetics in Japanese female breast cancer patients by using the population modeling approach.

Onoue H, Yano I, Tanaka A, Itohara K, Hanai A, Ishiguro H, Motohashi H, Masuda S, Matsubara K.

Eur J Clin Pharmacol. 2016 Jun;72(6):703-10. doi: 10.1007/s00228-016-2031-3. Epub 2016 Feb 23.

PMID:
26905999
41.

Pharmacokinetics and pharmacodynamics of mycophenolic acid in Nagase analbuminemic rats: Evaluation of protein binding effects using the modeling and simulation approach.

Yoshimura K, Yano I, Kawanishi M, Nakagawa S, Yonezawa A, Matsubara K.

Drug Metab Pharmacokinet. 2015 Dec;30(6):441-8. doi: 10.1016/j.dmpk.2015.10.004. Epub 2015 Nov 3.

PMID:
26643991
42.

Middle-aged to elderly women have a higher asymptomatic infection rate with Mycobacterium avium complex, regardless of body habitus.

Nishimura T, Fujita-Suzuki Y, Mori M, Carpenter SM, Fujiwara H, Uwamino Y, Tamizu E, Yano I, Kawabe H, Hasegawa N.

Respirology. 2016 Apr;21(3):553-5. doi: 10.1111/resp.12699. Epub 2015 Dec 7.

43.

[Effect of Water Intake on Allergy-like Events Associated with Non-ionic Iodine Contrast Agents].

Motoi R, Yano I, Ozaki J, Hokoyama K, Yamamoto T, Fukatsu S, Ishizuka R, Matsumura Y, Taniguchi M, Higashimura K, Matsubara K.

Yakugaku Zasshi. 2015;135(10):1177-84. doi: 10.1248/yakushi.15-00111. Japanese.

44.

Gefitinib and Erlotinib Lead to Phosphorylation of Eukaryotic Initiation Factor 2 Alpha Independent of Epidermal Growth Factor Receptor in A549 Cells.

Koyama S, Omura T, Yonezawa A, Imai S, Nakagawa S, Nakagawa T, Yano I, Matsubara K.

PLoS One. 2015 Aug 19;10(8):e0136176. doi: 10.1371/journal.pone.0136176. eCollection 2015.

45.

Computational Biology Tools for Identifying Specific Ligand Binding Residues for Novel Agrochemical and Drug Design.

Neshich IA, Nishimura L, de Moraes FR, Salim JA, Villalta-Romero F, Borro L, Yano IH, Mazoni I, Tasic L, Jardine JG, Neshich G.

Curr Protein Pept Sci. 2015;16(8):701-17.

PMID:
25961402
46.

Recurrence of disseminated Mycobacterium avium complex disease in a patient with anti-gamma interferon autoantibodies by reinfection.

Nishimura T, Fujita-Suzuki Y, Yonemaru M, Ohkusu K, Sakagami T, Carpenter SM, Otsuka Y, Namkoong H, Yano I, Hasegawa N.

J Clin Microbiol. 2015 Apr;53(4):1436-8. doi: 10.1128/JCM.03339-14. Epub 2015 Feb 4.

47.

Sensitive and validated LC-MS/MS methods to evaluate mycophenolic acid pharmacokinetics and pharmacodynamics in hematopoietic stem cell transplant patients.

Kawanishi M, Yano I, Yoshimura K, Yamamoto T, Hashi S, Masuda S, Kondo T, Takaori-Kondo A, Matsubara K.

Biomed Chromatogr. 2015 Sep;29(9):1309-16. doi: 10.1002/bmc.3423. Epub 2015 Jan 26.

48.

Comparison of the effects of azole antifungal agents on the anticoagulant activity of warfarin.

Yamamoto H, Habu Y, Yano I, Ozaki J, Kimura Y, Sato E, Shida A, Fukatsu S, Matsubara K.

Biol Pharm Bull. 2014;37(12):1990-3.

49.

Monitoring mycophenolate mofetil is necessary for the effective prophylaxis of acute GVHD after cord blood transplantation.

Arai Y, Kondo T, Kitano T, Hishizawa M, Yamashita K, Kadowaki N, Yamamoto T, Yano I, Matsubara K, Takaori-Kondo A.

Bone Marrow Transplant. 2015 Feb;50(2):312-4. doi: 10.1038/bmt.2014.258. Epub 2014 Nov 10. No abstract available.

PMID:
25387096
50.

Extracellular nucleotides from dying cells act as molecular signals to promote wound repair in renal tubular injury.

Nakagawa S, Omura T, Yonezawa A, Yano I, Nakagawa T, Matsubara K.

Am J Physiol Renal Physiol. 2014 Dec 15;307(12):F1404-11. doi: 10.1152/ajprenal.00196.2014. Epub 2014 Oct 29.

Supplemental Content

Support Center